Eton Pharmaceuticals, Inc. announced that Aucta Pharmaceuticals‘ New Drug Application for ET-105, an innovative formulation of lamotrigine which Eton acquired the U.S. marketing rights to in June 2019, has been accepted for review by the U.S. FDA. The FDA has assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of March 17, 2020.   Aucta is seeking approval for ET-105 as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, an...